Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls

Emanuele F Osimo, Toby Pillinger, Irene Mateos Rodriguez, Golam M Khandaker, Carmine M Pariante, Oliver D Howes, Emanuele F Osimo, Toby Pillinger, Irene Mateos Rodriguez, Golam M Khandaker, Carmine M Pariante, Oliver D Howes

Abstract

Importance: The magnitude and variability of cytokine alterations in depression are not clear.

Objective: To perform an up to date meta-analysis of mean differences of immune markers in depression, and to quantify and test for evidence of heterogeneity in immune markers in depression by conducting a meta-analysis of variability to ascertain whether only a sub-group of patients with depression show evidence of inflammation.

Data sources: Studies that reported immune marker levels in peripheral blood in patients with depression and matched healthy controls in the MEDLINE database from inception to August 29th 2018 were examined.

Study selection: Case-control studies that reported immune marker levels in peripheral blood in patients with depression and healthy controls were selected.

Data extraction and synthesis: Means and variances (SDs) were extracted for each measure to calculate effect sizes, which were combined using multivariate meta-analysis.

Main outcomes and measures: Hedges g was used to quantify mean differences. Relative variability of immune marker measurements in patients compared with control groups as indexed by the coefficient of variation ratio (CVR).

Results: A total of 107 studies that reported measurements from 5,166 patients with depression and 5,083 controls were included in the analyses. Levels of CRP (g = 0.71; 95%CI: 0.50-0.92; p < 0.0001); IL-3 (g = 0.60; 95%CI: 0.31-0.89; p < 0.0001); IL-6 (g = 0.61; 95%CI: 0.39-0.82; p < 0.0001); IL-12 (g = 1.18; 95%CI: 0.74-1.62; p < 0.0001); IL-18 (g = 1.97; 95%CI: 1.00-2.95; p < 0.0001); sIL-2R (g = 0.71; 95%CI: 0.44-0.98; p < 0.0001); and TNFα (g = 0.54; 95%CI: 0.32-0.76; p < 0.0001) were significantly higher in patients with depression. These findings were robust to a range of potential confounds and moderators. Mean-scaled variability, measured as CVR, was significantly lower in patients with depression for CRP (CVR = 0.85; 95%CI: 0.75-0.98; p = 0.02); IL-12 (CVR = 0.61; 95%CI: 0.46-0.80; p < 0.01); and sIL-2R (CVR = 0.85; 95%CI: 0.73-0.99; p = 0.04), while it was unchanged for IL-3, IL-6, IL-18, and TNF α.

Conclusions and relevance: Depression is confirmed as a pro-inflammatory state. Some of the inflammatory markers elevated in depression, including CRP and IL-12, show reduced variability in patients with depression, therefore supporting greater homogeneity in terms of an inflammatory phenotype in depression. Some inflammatory marker elevations in depression do not appear due to an inflamed sub-group, but rather to a right shift of the immune marker distribution.

Keywords: CRP; Cytokine; Depression; Heterogeneity; Inflammation; Meta-analysis.

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Figures

Fig. 1
Fig. 1
Forest plot showing effect sizes for mean differences in immune parameters in depression compared with healthy controls. There were significantly higher levels in patients with depression compared with controls for IL-1 α; IL-1 β; IL-2; IL-3; IL-6; IL-7; IL-8; IL-10; IL-12; IL-18; IL-1Ra; IL-2R; IL-6R; TNF α; and CRP. There was a significant reduction in IL-4 in patients compared with controls. There was no significant difference in TGF β; IFNγ; IL-13; IL-5 in patients compared with controls.
Fig. 2
Fig. 2
Forest plot showing effect sizes for mean-scaled variability of immune parameters in depression compared with healthy controls. The coefficient of variation ratio (CVR) was significant decreased for IL-12, IL-13, IL-2R, CRP, and IFNγ, indicating lower variability of these immune parameters in patients compared with controls, and significantly increased for IL-2 and TGF β, indicating increased variability of these immune parameters in patients compared with controls.

References

    1. Lim G.Y., Tam W.W., Lu Y., Ho C.S., Zhang M.W., Ho R.C. Prevalence of Depression in the Community from 30 Countries between 1994 and 2014. Scientific Rep. 2018;8(1):2861.
    1. Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G., Berk M. New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates—Nrf2 activators and GSK-3 inhibitors. Inflammopharmacol. 2012;20(3):127–150.
    1. Benros M.E., Waltoft B.L., Nordentoft M., Østergaard S.D., Eaton W.W., Krogh J. Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study. JAMAPsychiatry. 2013;70(8):812–820.
    1. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomatic Medicine. 2009;71(2):171–186.
    1. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K. A meta-analysis of cytokines in major depression. Biol. Psychiatry. 2010;67(5):446–457.
    1. Haapakoski R., Mathieu J., Ebmeier K.P., Alenius H., Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain, Behavior, Immun. 2015;49:206–215.
    1. Goldsmith D., Rapaport M., Miller B. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol. Psychiatry. 2016;21(12):1696–1709.
    1. Köhler C., Freitas T., Maes Md., De Andrade N., Liu C., Fernandes B. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr. Scand. 2017;135(5):373–387.
    1. Köhler O., Benros M.E., Nordentoft M., Farkouh M.E., Iyengar R.L., Mors O. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMAPsychiatry. 2014;71(12):1381–1391.
    1. Kappelmann N., Lewis G., Dantzer R., Jones P.B., Khandaker G.M. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry. 2016
    1. Khandaker G.M., Dantzer R., Jones P.B. Immunopsychiatry: important facts. Psychol. Medicine. 2017;47(13):2229–2237.
    1. Benedetti F., Lucca A., Brambilla F., Colombo C., Smeraldi E. Interleukine-6 serum levels correlate with response to antidepressant sleep deprivation and sleep phase advance. Prog. Neuro-Psychopharmacol. Biol. psychiatry. 2002;26(6):1167–1170.
    1. Lanquillon S., Krieg J.-C., Bening-Abu-Shach U., Vedder H. Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 2000;22(4):370–379.
    1. Carvalho L., Torre J., Papadopoulos A., Poon L., Juruena M., Markopoulou K. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J. Affect. Disord. 2013;148(1):136–140.
    1. Chamberlain S.R., Cavanagh J., de Boer P., Mondelli V., Jones D.N., Drevets W.C. Treatment-resistant depression and peripheral C-reactive protein. Br. J. Psychiatry. 2019;214(1):11–19.
    1. Maes M., Bosmans E., De Jongh R., Kenis G., Vandoolaeghe E., Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine. 1997;9(11):853–858.
    1. O’Brien S.M., Scully P., Fitzgerald P., Scott L.V., Dinan T.G. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J. Psychiatric Res. 2007;41(3–4):326–331.
    1. Kappelmann N., Lewis G., Dantzer R., Jones P.B., Khandaker G.M. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol. Psychiatry. 2018
    1. Raison C.L., Rutherford R.E., Woolwine B.J., Shuo C., Schettler P., Drake D.F. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMAPsychiatry. 2013;70(1):31–41.
    1. Khandaker G.M., Oltean B.P., Kaser M., Dibben C.R., Ramana R., Jadon D.R. Protocol for the insight study: a randomised controlled trial of single-dose tocilizumab in patients with depression and low-grade inflammation. BMJOpen. 2018;8(9)
    1. Brugger S.P., Howes O.D. Heterogeneity and homogeneity of regional brain structure in schizophrenia: a meta-analysis. JAMAPsychiatry. 2017;74(11):1104–1111.
    1. Pillinger T., Osimo E.F., Brugger S., Mondelli V., McCutcheon R.A., Howes O.D. A meta-analysis of immune parameters, variability, and assessment of modal distribution in psychosis and test of the immune subgroup hypothesis. Schizophr. Bull. 2018:sby160.
    1. Dierker L.C., Avenevoli S., Stolar M., Merikangas K. Smoking and depression: an examination of mechanisms of comorbidity. Am. J. Psychiatry. 2002;159(6):947–953.
    1. Stunkard A.J., Faith M.S., Allison K.C. Depression and obesity. Biological Psychiatry. 2003;54(3):330–337.
    1. Anda R.F., Williamson D.F., Escobedo L.G., Mast E.E., Giovino G.A., Remington P.L. Depression and the dynamics of smoking: a national perspective. JAMA. 1990;264(12):1541–1545.
    1. Nieman D.C., Henson D.A., Nehlsen-Cannarella S.L., Ekkens M., Utter A.C., Butterworth D.E. Influence of obesity on immune function. J. Am. Diet. Assoc. 1999;99(3):294–299.
    1. Brooks G.C., Blaha M.J., Blumenthal R.S. Relation of C-reactive protein to abdominal adiposity. The American journal of cardiology. 2010;106(1):56–61.
    1. Trayhurn P., Wood I.S. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br. J. Nutr. 2004;92(3):347–355.
    1. Yanbaeva D.G., Dentener M.A., Creutzberg E.C., Wesseling G., Wouters E.F. Systemic effects of smoking. Chest. 2007;131(5):1557–1566.
    1. Higgins J.P., White I.R., Anzures-Cabrera J. Meta-analysis of skewed data: combining results reported on log-transformed or raw scales. Stat. Med. 2008;27(29):6072–6092.
    1. Bender R., Bunce C., Clarke M., Gates S., Lange S., Pace N.L. Attention should be given to multiplicity issues in systematic reviews. J. Clin. Epidemiol. 2008;61(9):857–865.
    1. Eisler Z., Bartos I., Kertész J. Fluctuation scaling in complex systems: Taylor's law and beyond. Adv. Phys. 2008;57(1):89–142.
    1. Higgins J.P., Thompson S.G., Deeks J.J., Altman D.G. Measuring inconsistency in meta-analyses. BMJ. Br. Med. J. 2003;327(7414)::557.
    1. Alcocer-Gómez E., de Miguel M., Casas-Barquero N., Núñez-Vasco J., Sánchez-Alcazar J.A., Fernández-Rodríguez A. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav. Immun. 2014;36:111–117.
    1. Alesci S., Martinez P.E., Kelkar S., Ilias I., Ronsaville D.S., Listwak S.J. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. The Journal of Clinical Endocrinology & Metabolism. 2005;90(5):2522–2530.
    1. Ali N.S., Hashem A.H.H., Hassan A.M., Saleh A.A., El-Baz H.N. Serum interleukin-6 is related to lower cognitive functioning in elderly patients with major depression. Aging & mental health. 2018;22(5):655–661.
    1. Bai Y.-M., Chiou W.-F., Su T.-P., Li C.-T., Chen M.-H. Pro-inflammatory cytokine associated with somatic and pain symptoms in depression. J. Affect. Disord. 2014;155:28–34.
    1. Basterzi A.D., Aydemir Ç., Kisa C., Aksaray S., Tuzer V., Yazici K. IL-6 levels decrease with SSRI treatment in patients with major depression. Human Psychopharmacology: Clinical and Experimental. 2005;20(7):473–476.
    1. Berk M., Wadee A., Kuschke R., O'Neill-Kerr A. Acute phase proteins in major depression. J. Psychosom. Res. 1997;43(5):529–534.
    1. Boettger S., Müller H.-J., Oswald K., Puta C., Donath L., Gabriel H.H. Inflammatory changes upon a single maximal exercise test in depressed patients and healthy controls. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2010;34(3):475–478.
    1. Brambilla F., Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr. Scand. 1998;97(4):309–313.
    1. Camardese G., Pizi G., Marino M., Bartoccioni E., Grillo R., Mattioli B. Alterazioni delle risposte immuno-infiammatorie nei pazienti affetti da disturbo depressivo maggiore. Giorn Ital Psicopat. 2011;17:396–403.
    1. Cassano P., Bui E., Rogers A.H., Walton Z.E., Ross R., Zeng M. Inflammatory cytokines in major depressive disorder: A case–control study. Aust. N. Z. J. Psychiatry. 2017;51(1):23–31.
    1. Chamberlain S.R., Cavanagh J., de Boer P., Mondelli V., Jones D.N., Drevets W.C. Treatment-resistant depression and peripheral C-reactive protein. The British Journal of Psychiatry. 2018;1–9
    1. Charlton R.A., Lamar M., Zhang A., Ren X., Ajilore O., Pandey G.N. Associations between pro-inflammatory cytokines, learning, and memory in late-life depression and healthy aging. International journal of geriatric psychiatry. 2018;33(1):104–112.
    1. Chavda N., Kantharia N.D., J. Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression. Journal of pharmacology & pharmacotherapeutics. 2011;2(1)::11.
    1. Chen Y., Ouyang J., Liu S., Zhang S., Chen P., Jiang T. The Role of Cytokines in the Peripheral Blood of Major Depressive Patients. Clinical laboratory. 2017;63(7):1207–1212.
    1. Crnković D., Buljan D., Karlović D., Krmek M. Connection between inflammatory markers, antidepressants and depression. Acta clinica Croatica. 2012;51(1):25–32.
    1. Dannehl K., Rief W., Schwarz M.J., Hennings A., Riemer S., Selberdinger V. The predictive value of somatic and cognitive depressive symptoms for cytokine changes in patients with major depression. Neuropsych Dis Treat. 2014;10:1191.
    1. Davami M.H., Baharlou R., Vasmehjani A.A., Ghanizadeh A., Keshtkar M., Dezhkam I. Elevated IL-17 and TGF-β serum levels: a positive correlation between T-helper 17 cell-related pro-inflammatory responses with major depressive disorder. Basic and clinical neuroscience. 2016;7(2):137.
    1. Dhabhar F.S., Burke H.M., Epel E.S., Mellon S.H., Rosser R., Reus V.I. Low serum IL-10 concentrations and loss of regulatory association between IL-6 and IL-10 in adults with major depression. J. Psychiatr. Res. 2009;43(11):962–969.
    1. Dinan T., Siggins L., Scully P., O’Brien S., Ross P., Stanton C. Investigating the inflammatory phenotype of major depression: focus on cytokines and polyunsaturated fatty acids. J. Psychiatr. Res. 2009;43(4):471–476.
    1. Diniz B.S., Teixeira A.L., Talib L., Gattaz W.F., Forlenza O.V. Interleukin-1β serum levels is increased in antidepressant-free elderly depressed patients. The American Journal of Geriatric Psychiatry. 2010;18(2):172–176.
    1. Diniz B.S., Teixeira A.L., Talib L.L., Mendonça V.A., Gattaz W.F., Forlenza O.V. Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. J. Psychiatr. Res. 2010;44(14):917–920.
    1. Dome P., Teleki Z., Rihmer Z., Peter L., Dobos J., Kenessey I. Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul. Mol. Psychiatry. 2009;14(5):523.
    1. Dunjic-Kostic B., Ivkovic M., Radonjic N.V., Petronijevic N.D., Pantovic M., Damjanovic A. Melancholic and atypical major depression—Connection between cytokines, psychopathology and treatment. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2013;43:1–6.
    1. Elderkin-Thompson V., Irwin M.R., Hellemann G., Kumar A. Interleukin-6 and memory functions of encoding and recall in healthy and depressed elderly adults. The American Journal of Geriatric Psychiatry. 2012;20(9):753–763.
    1. Eller T., Vasar V., Shlik J., Maron E. Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2008;32(2):445–450.
    1. Elomaa A.-P., Niskanen L., Herzig K.-H., Viinamäki H., Hintikka J., Koivumaa-Honkanen H. Elevated levels of serum IL-5 are associated with an increased likelihood of major depressive disorder. BMC psychiatry. 2012;12(1):2.
    1. Euteneuer F., Schwarz M.J., Hennings A., Riemer S., Stapf T., Selberdinger V. Depression, cytokines and experimental pain: evidence for sex-related association patterns. J. Affect. Disord. 2011;131(1–3):143–149.
    1. Euteneuer F., Schwarz M.J., Dannehl K., Hartung A., Westermann S., Rief W. Increased soluble interleukin-2 receptor levels are related to somatic but not to cognitive-affective features in major depression. Brain Behav. Immun. 2012;26(8):1244–1248.
    1. Fan N., Luo Y., Ou Y., He H. Altered serum levels of TNF-α, IL-6, and IL-18 in depressive disorder patients. Human Psychopharmacology: Clinical and Experimental. 2017;32(4)
    1. Fornaro M., Martino M., Battaglia F., Colicchio S., Perugi G. Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. Neuropsych Dis Treat. 2011;7:51.
    1. Fornaro M., Rocchi G., Escelsior A., Contini P., Martino M. Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. J. Affect. Disord. 2013;145(3):300–307.
    1. Frodl T., Carballedo A., Hughes M., Saleh K., Fagan A., Skokauskas N. Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: high IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. Transl. Psychiatry. 2012;2(3)
    1. Frommberger U.H., Bauer J., Haselbauer P., Fräulin A., Riemann D., Berger M. Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur. Arch. Psychiatry Clin. Neurosci. 1997;247(4):228–233.
    1. Gazal M., Jansen K., Souza L.D., Oses J.P., Magalhães P.V., Pinheiro R. Association of interleukin-10 levels with age of onset and duration of illness in patients with major depressive disorder. Brazilian Journal of Psychiatry. 2015;37(4):296–302.
    1. Goyal S., Srivastava K., Kodange C., Bhat P. Immunological changes in depression. Industrial Psychiatry Journal. 2017;26(2):201–206.
    1. Grosse L., Ambrée O., Jörgens S., Jawahar M.C., Singhal G., Stacey D. Cytokine levels in major depression are related to childhood trauma but not to recent stressors. Psychoneuroendocrinology. 2016;73:24–31.
    1. Häfner S., Baghai T.C., Eser D., Schüle C., Rupprecht R., Bondy B. C-reactive protein is associated with polymorphisms of the angiotensin-converting enzyme gene in major depressed patients. J. Psychiatr. Res. 2008;2(42):163–165.
    1. Hernández M.E., Mendieta D., Martínez-Fong D., Loría F., Moreno J., Estrada I. Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur. Neuropsychopharmacol. 2008;18(12):917–924.
    1. Ho P.-S., Yen C.-H., Chen C.-Y., Huang S.-Y., Liang C.-S. Changes in cytokine and chemokine expression distinguish dysthymic disorder from major depression and healthy controls. Psychiatry Res. 2017;248:20–27.
    1. Hocaoglu C., Kural B., Aliyazıcıoglu R., Deger O., Cengiz S. IL-1β, IL-6, IL-8, IL-10, IFN-γ, TNF-α and its relationship with lipid parameters in patients with major depression. Metab. Brain Dis. 2012;27(4):425–430.
    1. Huang T.-L., Lin F.-C. High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2007;31(2):370–372.
    1. Hosseini R.F., Jabbari Azad F., Talaee A., Miri S., Mokhber N., Farid Hosseini F. Assessment of the immune system activity in Iranian patients with Major Depression Disorder (MDD) Iranian Journal of Immunology. 2007;4(1):38–43.
    1. Hughes M.M., Carballedo A., McLoughlin D.M., Amico F., Harkin A., Frodl T. Tryptophan depletion in depressed patients occurs independent of kynurenine pathway activation. Brain Behav. Immun. 2012;26(6):979–987.
    1. Hung Y.J., Hsieh C.H., Chen Y.J., Pei D., Kuo S.W., Shen D.C. Insulin sensitivity, proinflammatory markers and adiponectin in young males with different subtypes of depressive disorder. Clin. Endocrinol. 2007;67(5):784–789.
    1. Kageyama Y., Kasahara T., Kato M., Sakai S., Deguchi Y., Tani M. The relationship between circulating mitochondrial DNA and inflammatory cytokines in patients with major depression. J. Affect. Disord. 2018;233:15–20.
    1. Kagaya A., Kugaya A., Takebayashi M., Fukue-Saeki M., Saeki T., Yamawaki S. Plasma concentrations of interleukin-1β, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor α of depressed patients in Japan. Neuropsychobiology. 2001;43(2):59–62.
    1. Jozuka H., Jozuka E., Takeuchi S., Nishikaze O. Comparison of immunological and endocrinological markers associated with major depression. J. Int. Med. Res. 2003;31(1):36–41.
    1. Karlović D., Serretti A., Vrkić N., Martinac M., Marčinko D. Serum concentrations of CRP, IL-6, TNF-α and cortisol in major depressive disorder with melancholic or atypical features. Psychiatry Res. 2012;198(1):74–80.
    1. Kahl K.G., Schweiger U., Pars K., Kunikowska A., Deuschle M., Gutberlet M. Adrenal gland volume, intra-abdominal and pericardial adipose tissue in major depressive disorder. Psychoneuroendocrinology. 2015;58:1–8.
    1. Kéri S., Szabó C., Kelemen O. Blood biomarkers of depression track clinical changes during cognitive-behavioral therapy. J. Affect. Disord. 2014;164:118–122.
    1. Leo R., Di G.L., Tesauro M., Razzini C., Forleo G.B., Chiricolo G. Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. The Journal of clinical psychiatry. 2006;67(11):1760–1766.
    1. Lehto S.M., Huotari A., Niskanen L., Herzig K.-H., Tolmunen T., Viinamäki H. Serum IL-7 and G-CSF in major depressive disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2010;34(6):846–851.
    1. Lehto S.M., Niskanen L., Herzig K.-H., Tolmunen T., Huotari A., Viinamäki H. Serum chemokine levels in major depressive disorder. Psychoneuroendocrinology. 2010;35(2):226–232.
    1. Lee K.-M., Kim Y.-K. The role of IL-12 and TGF-β1 in the pathophysiology of major depressive disorder. Int. Immunopharmacol. 2006;6(8):1298–1304.
    1. Lee K.S., Chung J.H., Lee K.H., Shin M.-J., Oh B.H., Lee S.H. Simultaneous measurement of 23 plasma cytokines in late-life depression. Neurological sciences. 2009;30(5):435–438.
    1. Kubera M., Kenis G., Bosmans E., Zieba A., Dudek D., Nowak G. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol. J. Pharmacol. 2000;52(3):237–241.
    1. Kokai M., Kashiwamura S-i, Okamura H., Ohara K., Morita Y. Plasma interleukin-18 levels in patients with psychiatric disorders. J. Immunother. 2002;25:S68–S71.
    1. Kling M.A., Alesci S., Csako G., Costello R., Luckenbaugh D.A., Bonne O. Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol. Psychiatry. 2007;62(4):309–313.
    1. Kim Y., Suh I., Kim H., Han C., Lim C., Choi S. The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry. 2002;7(10):1107.
    1. Maes M., Bosmans E., Suy E., Vandervorst C., De Jonckheere C., Raus J. Immune disturbances during major depression: upregulated expression of interleukin-2 receptors. Neuropsychobiology. 1990;24(3):115–120.
    1. Miller G.E., Rohleder N., Stetler C., Kirschbaum C. Clinical depression and regulation of the inflammatory response during acute stress. Psychosom. Med. 2005;67(5):679–687.
    1. Mikova O., Yakimova R., Bosmans E., Kenis G., Maes M. Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur. Neuropsychopharmacol. 2001;11(3):203–208.
    1. Merendino R.A., Di Rosa A.E., Di Pasquale G., Minciullo P.L., Mangraviti C., Costantino A. Interleukin-18 and CD30 serum levels in patients with moderate-severe depression. Mediators Inflamm. 2002;11(4):265–267.
    1. Marques-Deak A., Neto F.L., Dominguez W., Solis A., Kurcgant D., Sato F. Cytokine profiles in women with different subtypes of major depressive disorder. J. Psychiatr. Res. 2007;41(1–2):152–159.
    1. Manoharan A., Rajkumar R.P., Shewade D.G., Sundaram R., Muthuramalingam A., Paul A. Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine. Human Psychopharmacology: Clinical and Experimental. 2016;31(3):178–184.
    1. O'donovan A, Rush G, Hoatam G, Hughes BM, McCrohan A, Kelleher C, Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depression and anxiety. 2013;30(4):307–314.
    1. O'brien SM, Scott LV, Dinan TG. Antidepressant therapy and C-reactive protein levels. The British Journal of Psychiatry. 2006;188(5):449–452.
    1. Nunes S.O.V., Vargas H.O., Brum J., Prado E., Vargas M.M., Castro M.R.Pd. A comparison of inflammatory markers in depressed and nondepressed smokers. Nicotine Tob. Res. 2011;14(5):540–546.
    1. Narita K., Murata T., Takahashi T., Kosaka H., Omata N., Wada Y. Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2006;30(6):1159–1162.
    1. Munjiza A., Kostic M., Pesic D., Gajic M., Markovic I., Tosevski D.L. Higher concentration of interleukin 6-A possible link between major depressive disorder and childhood abuse. Psychiatry Res. 2018;264:26–30.
    1. Motivala S.J., Sarfatti A., Olmos L., Irwin M.R. Inflammatory markers and sleep disturbance in major depression. Psychosom. Med. 2005;67(2):187–194.
    1. Mota R., Gazal M., Acosta B.A., de Leon P.B., Jansen K., Pinheiro R.T. Interleukin-1β is associated with depressive episode in major depression but not in bipolar disorder. J. Psychiatr. Res. 2013;47(12):2011–2014.
    1. Piletz J.E., Halaris A., Iqbal O., Hoppensteadt D., Fareed J., Zhu H. Pro-inflammatory biomakers in depression: treatment with venlafaxine. The World Journal of Biological Psychiatry. 2009;10(4):313–323.
    1. Pike J.L., Irwin M.R. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav. Immun. 2006;20(2):169–174.
    1. Pavón L., Sandoval-López G., Hernández M.E., Loría F., Estrada I., Pérez M. Th2 cytokine response in major depressive disorder patients before treatment. J. Neuroimmunol. 2006;172(1–2):156–165.
    1. Owen B., Eccleston D., Ferrier I., Young H. Raised levels of plasma interleukin-1β in major and postviral depression. Acta Psychiatr. Scand. 2001;103(3):226–228.
    1. Ogłodek E.A. Changes in the concentrations of inflammatory and oxidative status biomediators (MIP-1 α, PMN elastase, MDA, and IL-12) in depressed patients with and without posttraumatic stress disorder. Pharmacol. Rep. 2018;70(1):110–118.
    1. Tuglu C., Kara S.H., Caliyurt O., Vardar E., Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology. 2003;170(4):429–433.
    1. Thomas A.J., Davis S., Morris C., Jackson E., Harrison R., O’Brien J.T. Increase in interleukin-1β in late-life depression. Am. J. Psychiatry. 2005;162(1):175–177.
    1. Sutcigil L., Oktenli C., Musabak U., Bozkurt A., Cansever A., Uzun O. Pro-and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clinical and Developmental Immunology. 2008;2007
    1. Sowa-Kućma M., Styczeń K., Siwek M., Misztak P., Nowak R.J., Dudek D. Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of illness, episode number, suicidal ideation and prior suicide attempts. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2018;81:372–383.
    1. Sluzewska A., Rybakowski J., Bosmans E., Sobieska M., Berghmans R., Maes M. Indicators of immune activation in major depression. Psychiatry Res. 1996;64(3):161–167.
    1. Simon N., McNamara K., Chow C., Maser R., Papakostas G., Pollack M. A detailed examination of cytokine abnormalities in major depressive disorder. Eur. Neuropsychopharmacol. 2008;18(3):230–233.
    1. Seidel A., Arolt V., Hunstiger M., Rink L., Behnisch A., Kirchner H. Cytokine production and serum proteins in depression. Scand. J. Immunol. 1995;41(6):534–538.
    1. Schlatter J., Ortuno F., Cervera-Enguix S. Monocytic parameters in patients with dysthymia versus major depression. J. Affect. Disord. 2004;78(3):243–247.
    1. Savitz J., Drevets W.C., Wurfel B.E., Ford B.N., Bellgowan P.S., Victor T.A. Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav. Immun. 2015;46:55–59.
    1. Rybka J., Kędziora-Kornatowska K., Banaś-Leżańska P., Majsterek I., Carvalho L.A., Cattaneo A. Interplay between the pro-oxidant and antioxidant systems and proinflammatory cytokine levels, in relation to iron metabolism and the erythron in depression. Free Radical Biol. Med. 2013;63:187–194.
    1. Rudzki L., Pawlak D., Pawlak K., Waszkiewicz N., Małus A., Konarzewska B. Immune suppression of IgG response against dairy proteins in major depression. BMC psychiatry. 2017;17(1):268.
    1. Rudolf S., Greggersen W., Kahl K.G., Hüppe M., Schweiger U. Elevated IL-6 levels in patients with atypical depression but not in patients with typical depression. Psychiatry Res. 2014;217(1–2):34–38.
    1. Rizavi H.S., Ren X., Zhang H., Bhaumik R., Pandey G.N. Abnormal gene expression of proinflammatory cytokines and their membrane-bound receptors in the lymphocytes of depressed patients. Psychiatry Res. 2016;240:314–320.
    1. Rief W., Pilger F., Ihle D., Bosmans E., Egyed B., Maes M. Immunological differences between patients with major depression and somatization syndrome. Psychiatry Res. 2001;105(3):165–174.
    1. Rawdin B., Mellon S., Dhabhar F., Epel E., Puterman E., Su Y. Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav. Immun. 2013;31:143–152.
    1. Sugimoto K., Kakeda S., Watanabe K., Katsuki A., Ueda I., Igata N. Relationship between white matter integrity and serum inflammatory cytokine levels in drug-naive patients with major depressive disorder: diffusion tensor imaging study using tract-based spatial statistics. Transl. Psychiatry. 2018;8(1):141.
    1. Shen Y., Lu P., Wei L., Hu X., Chen W. Fluoxetine treatment for major depression decreases the plasma levels of cytokines. Afr. J. Biotechnol. 2010;9(43):7346–7351.
    1. Schmidt F.M., Lichtblau N., Minkwitz J., Chittka T., Thormann J., Kirkby K.C. Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. J. Psychiatr. Res. 2014;55:29–34.
    1. Zoga M., Oulis P., Chatzipanagiotou S., Masdrakis V.G., Pliatsika P., Boufidou F. Indoleamine 2, 3-dioxygenase and immune changes under antidepressive treatment in major depression in females. in vivo. 2014;28(4):633–638.
    1. Zincir S., Öztürk P., Bilgen A.E., Izci F., Yükselir C. Levels of serum immunomodulators and alterations with electroconvulsive therapy in treatment-resistant major depression. Neuropsych Dis Treat. 2016;12:1389.
    1. Zou W., Feng R., Yang Y. Changes in the serum levels of inflammatory cytokines in antidepressant drug-naïve patients with major depression. PLoS ONE. 2018;13(6)
    1. Yoshimura R., Umene-Nakano W., Hoshuyama T., Ikenouchi-Sugita A., Hori H., Katsuki A. Plasma levels of brain-derived neurotrophic factor and interleukin-6 in patients with dysthymic disorder: comparison with age-and sex-matched major depressed patients and healthy controls. Human Psychopharmacology: Clinical and Experimental. 2010;25(7–8):566–569.
    1. Yoshimura R., Hori H., Ikenouchi-Sugita A., Umene-Nakano W., Ueda N., Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI-or SNRI-refractory depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 2009;33(4):722–726.
    1. Yang K., Xie G., Zhang Z., Wang C., Li W., Zhou W. Levels of serum interleukin (IL)-6, IL-1β, tumour necrosis factor-α and leptin and their correlation in depression. Aust. N. Z. J. Psychiatry. 2007;41(3):266–273.
    1. Xia Q.-R., Liang J., Cao Y., Shan F., Liu Y., Xu Y.-Y. Increased plasma nesfatin-1 levels may be associated with corticosterone, IL-6, and CRP levels in patients with major depressive disorder. Clin. Chim. Acta. 2018;480:107–111.
    1. Wiener C.D., Moreira F.P., Cardoso T.A., Mondin T.C., da Silva Magalhães P.V., Kapczinski F. Inflammatory cytokines and functional impairment in drug-free subjects with mood disorder. J. Neuroimmunol. 2017;307:33–36.
    1. Vaccarino V., Brennan M.-L., Miller A.H., Bremner J.D., Ritchie J.C., Lindau F. Association of major depressive disorder with serum myeloperoxidase and other markers of inflammation: a twin study. Biol. Psychiatry. 2008;64(6):476–483.
    1. Wang S., Zhong H., Lu M., Song G., Zhang X., Lin M. Higher Serum C Reactive Protein Determined C Reactive Protein Single-Nucleotide Polymorphisms Are Involved in Inherited Depression. Psychiatry investigation. 2018;15(8):824.
    1. Rapaport M.H., Irwin M. Serum soluble interleukin-2 receptors and natural killer cell function in major depression. Research Communications in Biological Psychology and Psychiatry. 1996;21(1/2):73–76.
    1. Osimo E.F., Baxter L.J., Lewis G., Jones P.B., Khandaker G.M. Prevalence of Low-grade Inflammation in Depression: a systematic review and meta-analysis of CRP levels. Psychol. Med. 2019 E-pub ahead of print:1-13.
    1. Miller G.E., Cole S.W. Clustering of depression and inflammation in adolescents previously exposed to childhood adversity. Biol. Psychiatry. 2012;72(1):34–40.
    1. Yeh E.T. CRP as a mediator of disease. Circulation. 2004;109(21_suppl_1) II-11-II-4.
    1. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321(7255):199–204.
    1. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., Harris T.B. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22):2131–2135.
    1. Fernandes B., Steiner J., Bernstein H., Dodd S., Pasco J., Dean O. C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. Mol. Psychiatry. 2016;21(4):554.
    1. von Känel R., Hepp U., Kraemer B., Traber R., Keel M., Mica L. Evidence for low-grade systemic proinflammatory activity in patients with posttraumatic stress disorder. J. Psychiatr. Res. 2007;41(9):744–752.
    1. Fernandes B.S., Steiner J., Molendijk M.L., Dodd S., Nardin P., Gonçalves C.-A. C-reactive protein concentrations across the mood spectrum in bipolar disorder: a systematic review and meta-analysis. The Lancet Psychiatry. 2016;3(12):1147–1156.
    1. Gimeno D., Kivimäki M., Brunner E.J., Elovainio M., De Vogli R., Steptoe A. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol. Med. 2009;39(3):413–423.
    1. Khandaker G.M., Pearson R.M., Zammit S., Lewis G., Jones P.B. Association of serum interleukin 6 and C-reactive protein in childhood with depression and psychosis in young adult life: a population-based longitudinal study. JAMA psychiatry. 2014;71(10):1121–1128.
    1. Wium-Andersen M.K., Ørsted D.D., Nielsen S.F., Nordestgaard B.G. Elevated C-reactive protein levels, psychological distress, and depression in 73 131 individuals. JAMA psychiatry. 2013;70(2):176–184.
    1. Zalli A., Jovanova O., Hoogendijk W., Tiemeier H., Carvalho L. Low-grade inflammation predicts persistence of depressive symptoms. Psychopharmacology. 2016;233(9):1669–1678.
    1. Khandaker G.M., Zuber V., Rees J.M.B., Carvalho L., Mason A.M., Foley C.N. Shared mechanism between depression and coronary heart disease: findings from Mendelian randomization analysis of a large UK population-based cohort. Mol. Psychiatry. 2019
    1. Felger J.C., Haroon E., Patel T.A., Goldsmith D.R., Wommack E.C., Woolwine B.J. What does plasma CRP tell us about peripheral and central inflammation in depression? Mol. Psychiatry. 2018
    1. Abbas A.K., Lichtman A.H., Pillai S. Cellular and molecular immunology E-book. Elsevier Health Sciences. 2014
    1. Stern A.S., Magram J., Presky D.H. Interleukin-12 an integral cytokine in the immune response. Life Sci. 1996;58(8):639–654.
    1. Fayers P. Alphas, betas and skewy distributions: two ways of getting the wrong answer. Adv Health Sci Educ. 2011;16(3):291–296.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel